RecruitingPhase 3NCT06441630

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension


Sponsor

Addpharma Inc.

Enrollment

251 participants

Start Date

Jul 31, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study tests the safety and effectiveness of a combination treatment using two drugs — AD-227A and AD-227B — for people with essential hypertension (high blood pressure with no identifiable underlying cause). The goal is to see if the combination controls blood pressure better than current options. **You may be eligible if...** - You have been diagnosed with essential (primary) hypertension — high blood pressure without a known secondary cause - You meet other inclusion criteria as determined by the study team **You may NOT be eligible if...** - You have secondary hypertension (high blood pressure caused by another medical condition, such as kidney disease or a hormone disorder) - You meet other exclusion criteria as determined by the study team Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAD-227A

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUGAD-227B

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUGAD-227C

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUGPlacebo of AD-227B

Per Oral, 1 Tablet, Once a day for 8 weeks

DRUGPlacebo of AD-227C

Per Oral, 1 Tablet, Once a day for 8 weeks


Locations(1)

Gangnam CHA Medical Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06441630


Related Trials